Enormous savings in first level treatment costs (one case of metastasized CRC represents substantial treatment costs).
Reduced second level treatment costs.
9 Annual cost for late-stage treatment – National Center for Biotechnology Information.10 https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening
In addition to our flagship ColoAlert product, Mainz Biomed is also developing:
Developing a novel early detection pancreatic cancer screening test
If you would like to be kept up to date with the very latest news, please enter your details in the form and we will keep you updated.